US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Alamar Biosciences / Equity Capital Markets

<ul>
<li>IPO terms set for $15.00–$17.00 per share, targeting ~$1.1B valuation and ~$133M in proceeds to scale commercial, manufacturing, and R&amp;D operations.</li>
<li>Commercial-Stage proteomics company generating $74.2M revenue in 2025, leveraging proprietary NULISA platform for ultra-sensitive biomarker detection across research and diagnostics.</li>
<li>Strong investor backing and momentum with $300M+ raised, Qiming Ventures as largest holder (16.2%), and IPO expected to trade April 17.</li>
</ul>


IPO terms set for $15.00–$17.00 per share, targeting ~$1.1B valuation and ~$133M in proceeds to scale commercial, manufacturing, and R&amp;D operations.
Commercial-Stage proteomics company generating $74.2M revenue in 2025, leveraging proprietary NULISA platform for ultra-sensitive biomarker detection across research and diagnostics.
Strong investor backing and momentum with $300M+ raised, Qiming Ventures as largest holder (16.2%), and IPO expected to trade April 17.


Alamar Biosciences (ALMR): Revenue Generating Protein Detection Platform Sets Terms for IPO

<ul>
<li>Commercial-Stage proteomics company leveraging its proprietary NULISA platform to enable ultra-sensitive, high-plex protein detection for early disease detection and advanced research applications.</li>
<li>Demonstrates strong growth with revenue increasing from $25.1M to $74.2M (FY24–FY25), rapid customer adoption, and expanding instrument and assay utilization globally.</li>
<li>Backed by leading investors including Sands Capital, Illumina Ventures, and T. Rowe Price; filed for IPO March 27, positioning to capitalize on ~$50B+ growing proteomics and diagnostics markets.</li>
</ul>


Commercial-Stage proteomics company leveraging its proprietary NULISA platform to enable ultra-sensitive, high-plex protein detection for early disease detection and advanced research applications.
Demonstrates strong growth with revenue increasing from $25.1M to $74.2M (FY24–FY25), rapid customer adoption, and expanding instrument and assay utilization globally.
Backed by leading investors including Sands Capital, Illumina Ventures, and T. Rowe Price; filed for IPO March 27, positioning to capitalize on ~$50B+ growing proteomics and diagnostics markets.


Alamar Biosciences (ALMR): Peeking at the IPO Prospectus of a Protein Detection & Analysis Biotech

Attovia Therapeutics / Equity Capital Markets

<ul>
<li>Innovative biologics platform: Company’s ATTOBODY technology supports a pipeline of next-generation immune disease therapies.</li>
<li>Lead program advances: ATTO-1310 has completed Phase 1 dosing with encouraging early data in chronic pruritic diseases.</li>
<li>Early-Stage opportunity: Strong biotech sentiment supports the IPO, but limited clinical maturity creates execution risk.</li>
</ul>


Innovative biologics platform: Company’s ATTOBODY technology supports a pipeline of next-generation immune disease therapies.
Lead program advances: ATTO-1310 has completed Phase 1 dosing with encouraging early data in chronic pruritic diseases.
Early-Stage opportunity: Strong biotech sentiment supports the IPO, but limited clinical maturity creates execution risk.


Attovia Therapeutics (ATTO): ATTOBODY Platform Draws Interest with Sector Dedicated Investors

<ul>
<li>Clinical-Stage biotech leveraging the proprietary ATTOBODY platform, with lead candidate ATTO-1310 completing Phase 1 and two additional pipeline programs advancing toward the clinic.</li>
<li>Seeking approximately $182 million to fund clinical development, expand its pipeline, and support operations as it advances multiple immune-mediated disease programs.</li>
<li>Early-Stage, Phase 1 IPO backed by Frazier Life Sciences and licensed from Alamar Biosciences, making institutional demand likely to be the key trading catalyst.</li>
</ul>


Clinical-Stage biotech leveraging the proprietary ATTOBODY platform, with lead candidate ATTO-1310 completing Phase 1 and two additional pipeline programs advancing toward the clinic.
Seeking approximately $182 million to fund clinical development, expand its pipeline, and support operations as it advances multiple immune-mediated disease programs.
Early-Stage, Phase 1 IPO backed by Frazier Life Sciences and licensed from Alamar Biosciences, making institutional demand likely to be the key trading catalyst.


Attovia Therapeutics (ATTO): Phase 1 Immune Therapy Biotech Sets Terms for IPO

<ul>
<li>Avalyn Pharma Inc. prices IPO at $16–$18/share, offering 11.8M shares to fund inhaled fibrosis therapies, targeting ~$591M–$665M valuation.</li>
<li>Clinical-Stage pipeline led by AP01 and AP02 aims to treat IPF and PPF via inhaled antifibrotics, addressing high unmet need in interstitial lung disease.</li>
<li>Backed by top-tier underwriters including Morgan Stanley and Jefferies; CEO Lyn Baranowski brings deep respiratory biotech experience and strong M&amp;A track record.</li>
</ul>


Avalyn Pharma Inc. prices IPO at $16–$18/share, offering 11.8M shares to fund inhaled fibrosis therapies, targeting ~$591M–$665M valuation.
Clinical-Stage pipeline led by AP01 and AP02 aims to treat IPF and PPF via inhaled antifibrotics, addressing high unmet need in interstitial lung disease.
Backed by top-tier underwriters including Morgan Stanley and Jefferies; CEO Lyn Baranowski brings deep respiratory biotech experience and strong M&amp;A track record.


Avalyn Pharma (AVLN): Phase 2 Biotech for Treatment of Pulmonary Fibrosis Sets Terms for IPO

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Alamar Biosciences (ALMR US)

Alamar Biosciences (ALMR): Revenue Generating Protein Detection Platform Sets Terms for IPO

Proteomics company sets IPO terms at $15.00–$17.00 per share, targeting $1.1B valuation to scale operations and leverage NULISA platform for...

IPO Boutique

Alamar Biosciences (ALMR): Peeking at the IPO Prospectus of a Protein Detection & Analysis Biotech

Proteomics company with NULISA platform sees revenue growth, customer adoption, and IPO filing to capitalize on expanding markets.

IPO Boutique

Attovia Therapeutics (ATTO): ATTOBODY Platform Draws Interest with Sector Dedicated Investors

Company's innovative ATTOBODY technology shows promise for next-gen immune disease therapies, with lead program ATTO-1310 showing encouraging...

IPO Boutique

Attovia Therapeutics (ATTO): Phase 1 Immune Therapy Biotech Sets Terms for IPO

Clinical-Stage biotech with ATTOBODY platform seeks funding for immune-mediated disease programs, including lead candidate ATTO-1310. Early-Stage...

IPO Boutique

Avalyn Pharma (AVLN): Phase 2 Biotech for Treatment of Pulmonary Fibrosis Sets Terms for IPO

Avalyn Pharma Inc. prices IPO to fund inhaled fibrosis therapies, targeting high valuation; clinical-stage pipeline aims to treat IPF and PPF with...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Alamar Biosciences (ALMR): Revenue Generating Protein Detection Platform Sets Terms for IPO

​Proteomics company sets IPO terms at $15.00–$17.00 per share, targeting $1.1B valuation to scale operations and leverage NULISA platform for...

IPO Boutique

Alamar Biosciences (ALMR): Peeking at the IPO Prospectus of a Protein Detection & Analysis Biotech

​Proteomics company with NULISA platform sees revenue growth, customer adoption, and IPO filing to capitalize on expanding markets.

IPO Boutique

Attovia Therapeutics (ATTO): ATTOBODY Platform Draws Interest with Sector Dedicated Investors

​Company's innovative ATTOBODY technology shows promise for next-gen immune disease therapies, with lead program ATTO-1310 showing encouraging...

IPO Boutique

Attovia Therapeutics (ATTO): Phase 1 Immune Therapy Biotech Sets Terms for IPO

​Clinical-Stage biotech with ATTOBODY platform seeks funding for immune-mediated disease programs, including lead candidate ATTO-1310. Early-Stage...

IPO Boutique

Avalyn Pharma (AVLN): Phase 2 Biotech for Treatment of Pulmonary Fibrosis Sets Terms for IPO

​Avalyn Pharma Inc. prices IPO to fund inhaled fibrosis therapies, targeting high valuation; clinical-stage pipeline aims to treat IPF and PPF with...

IPO Boutique

Proteomics company sets IPO terms at $15.00–$17.00 per share, targeting $1.1B valuation to scale operations and leverage NULISA platform for...

Proteomics company with NULISA platform sees revenue growth, customer adoption, and IPO filing to capitalize on expanding markets.

Company's innovative ATTOBODY technology shows promise for next-gen immune disease therapies, with lead program ATTO-1310 showing encouraging...

Clinical-Stage biotech with ATTOBODY platform seeks funding for immune-mediated disease programs, including lead candidate ATTO-1310. Early-Stage...

Avalyn Pharma Inc. prices IPO to fund inhaled fibrosis therapies, targeting high valuation; clinical-stage pipeline aims to treat IPF and PPF with...